PHAT Stock Price | Phathom Pharmaceuticals Inc P/E, Revenue, EPS, & Forecasts

Phathom Pharmaceuticals Inc • PHAT

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Phathom Pharmaceuticals Inc

Ticker

PHAT

Trading on

NASDAQ

ISIN

US71722W1071

Industry

Biotechnology

Sector

Healthcare

CEO

Steven L. Basta M.B.A.

Headquarters

100 Campus Drive, Florham Park, NJ, United States, 07932

Employees

427

Website

phathompharma.com

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Metrics

BasicAdvanced

Market cap

$1.05B

P/E ratio

EPS

-$3.76

Dividend Yield

0.00%

Beta

0.45

Forward P/E ratio

EBIDTA

$-213M

Ex dividend date

Price & volume

Market cap

$1.05B

Average daily volume

0.8M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

7.1

Price to book

25.37

Earnings

EPS

-$3.76

EPS estimate (current quarter)

-$0.42

EPS estimate (next quarter)

-$0.24

EBITDA

$-213M

Revenues (TTM)

$147M

Revenues per share (TTM)

$2.04

Technicals

Beta

0.45

52-week High

$16.27

52-week Low

$2.21

50-day moving average

$13.40

200-day moving average

$8.89

Short ratio

12.58

Short %

30.30%

Management effectiveness

ROE (TTM)

-3,489.00%

ROA (TTM)

-42.54%

Profit margin

-186.53%

Gross profit margin

$128M

Operating margin

-30.85%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

202.70%

Share stats

Outstanding Shares

71.1M

Float

50.3M

Insiders %

4.51%

Institutions %

87.77%

Analyst Insights & forecasts

89% Buy

11% Hold

0% Sell

Based on information from 9 analysts.

Average price target

$23.13

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$1.05

-$1.08

2.78%

Q4 • 24Beat

-$1.07

-0.38%

Q1 • 25Missed

-$0.79

-$0.91

13.19%

Q2 • 25Beat

-$0.15

-$0.47

68.09%

Q3 • 25Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$39.5M

$-75.8M

-191.91%

Q2 • 25

$49.5M

$-30M

-60.55%

Q3 • 25

25.32%

-60.46%

-68.45%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$250M

$656M

262.19%

Q2 • 25

$240M

$663M

275.84%

Q3 • 25

-3.97%

1.03%

5.21%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-62.7M

$-0.1M

$0.1M

$-62.7M

Q2 • 25

$-14.1M

$-0M

$-0.3M

$-14.1M

Q3 • 25

-77.50%

-72.16%

-438.75%

-77.50%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Phathom Pharmaceuticals Inc share?

Phathom Pharmaceuticals Inc shares are currently traded for undefined per share.

How many shares does Phathom Pharmaceuticals Inc have?

Phathom Pharmaceuticals Inc currently has 71.1M shares.

Does Phathom Pharmaceuticals Inc pay dividends?

No, Phathom Pharmaceuticals Inc doesn't pay dividends.

What is Phathom Pharmaceuticals Inc 52 week high?

Phathom Pharmaceuticals Inc 52 week high is $16.27.

What is Phathom Pharmaceuticals Inc 52 week low?

Phathom Pharmaceuticals Inc 52 week low is $2.21.

What is the 200-day moving average of Phathom Pharmaceuticals Inc?

Phathom Pharmaceuticals Inc 200-day moving average is $8.89.

Who is Phathom Pharmaceuticals Inc CEO?

The CEO of Phathom Pharmaceuticals Inc is Steven L. Basta M.B.A..

How many employees Phathom Pharmaceuticals Inc has?

Phathom Pharmaceuticals Inc has 427 employees.

What is the market cap of Phathom Pharmaceuticals Inc?

The market cap of Phathom Pharmaceuticals Inc is $1.05B.

What is the P/E of Phathom Pharmaceuticals Inc?

The current P/E of Phathom Pharmaceuticals Inc is null.

What is the EPS of Phathom Pharmaceuticals Inc?

The EPS of Phathom Pharmaceuticals Inc is -$3.76.

What is the PEG Ratio of Phathom Pharmaceuticals Inc?

The PEG Ratio of Phathom Pharmaceuticals Inc is null.

What do analysts say about Phathom Pharmaceuticals Inc?

According to the analysts Phathom Pharmaceuticals Inc is considered a buy.